31731005Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QMContemporary clinical trialsBenzothiazoles; CCR5 Receptor Antagonists; Imidazoles; Isoxazoles; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; SulfoxidesClinical Trials, Phase II as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Receptors, CCR2; Treatment OutcomeA randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemp Clin Trials. 2020 01; 88:105889.Contemp Clin Trials2019-11-13T00:00:002019A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMichaelCharltonMichael Charlton0.000000000000000.000000000000003423Charlton, MichaelProfessorD007093Chemicals & Drugs1061630.909045ImidazolesD004311Procedures33818220.708936Double-Blind MethodD004359Procedures2748930.819188Drug Therapy, CombinationMedicine-GastroenterologyD007555Chemicals & Drugs26770.957698IsoxazolesD008103Disorders832960.817731Liver CirrhosisAuthorship 13427360.1846370.1846372authors10.2516has subject areaD013454Chemicals & Drugs660.991063SulfoxidesD006801Living Beings2262862810.130052HumansD015337Concepts & IdeasProcedures971560.952363Multicenter Studies as TopicD016032Concepts & IdeasProcedures2778500.730116Randomized Controlled Trials as TopicD017322Activities & BehaviorsProcedures661730.916814Clinical Trials, Phase II as TopicD016896Concepts & Ideas101179490.402389Treatment OutcomeD018160Chemicals & Drugs671220.931349Receptors, Cytoplasmic and NuclearAuthorship 1508065MaryRinellaMary Rinella41.7886000000000087.598699999999994118Rinella, MaryProfessorD052160Chemicals & Drugs13170.987931BenzothiazolesD054390Chemicals & Drugs20350.982671Receptors, CCR2D065100Chemicals & Drugs220.998159CCR5 Receptor AntagonistsD065626Disorders362100.759716Non-alcoholic Fatty Liver DiseaseUniversity of Chicagotrue1ProfessorProfessortrue1ProfessorProfessor